Detalle Publicación


PD-L1 crosslinking as a new strategy of 4-1BB agonism immunotherapy

Autores: Shu, F.; Punekar, S. R.; Velcheti, V.; Fernández de Sanmamed Gutiérrez, Miguel; Wang, J. (Autor de correspondencia)
Título de la revista: CLINICAL CANCER RESEARCH
ISSN: 1078-0432
Volumen: 28
Número: 15
Páginas: 3182 - 3184
Fecha de publicación: 2022
-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agents demonstrated significant liver immuno-toxicity. A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with a bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule PD-L1. See related article by Peper-Gabriel et al., p. 3387.